Shortly after the FDA approved the much-anticipated Alzheimer’s drug Leqembi as an intravenous infusion, Eisai announced positive results from a study examining a subcutaneous formulation…
There was a problem reporting this post.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.